MA31265B1 - Traitement du cancer au moyen de l'il-18 humaine combinee a un anticorps anti-cd20 - Google Patents

Traitement du cancer au moyen de l'il-18 humaine combinee a un anticorps anti-cd20

Info

Publication number
MA31265B1
MA31265B1 MA32235A MA32235A MA31265B1 MA 31265 B1 MA31265 B1 MA 31265B1 MA 32235 A MA32235 A MA 32235A MA 32235 A MA32235 A MA 32235A MA 31265 B1 MA31265 B1 MA 31265B1
Authority
MA
Morocco
Prior art keywords
treatment
human cancer
antibodies coupled
human
antibodies
Prior art date
Application number
MA32235A
Other languages
Arabic (ar)
English (en)
Inventor
Zdenka Haskova
Zdenka Ludmila Jonak
Stephen H Trulli
John F Toso
Margaret N Whitacre
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39788932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31265(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA31265B1 publication Critical patent/MA31265B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne d'une manière générale l'utilisation de l'il-18 humaine en combinaison dans le traitement de cancers. Cette invention concerne en particulier l'utilisation de l'il-18 humaine combinée à un anticorps anti-cd20.
MA32235A 2007-03-23 2009-09-24 Traitement du cancer au moyen de l'il-18 humaine combinee a un anticorps anti-cd20 MA31265B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89685507P 2007-03-23 2007-03-23
US95200207P 2007-07-26 2007-07-26
PCT/US2008/057620 WO2008118736A1 (fr) 2007-03-23 2008-03-20 Traitement du cancer au moyen de l'il-18 humaine combinée à un anticorps anti-cd20

Publications (1)

Publication Number Publication Date
MA31265B1 true MA31265B1 (fr) 2010-03-01

Family

ID=39788932

Family Applications (2)

Application Number Title Priority Date Filing Date
MA32235A MA31265B1 (fr) 2007-03-23 2009-09-24 Traitement du cancer au moyen de l'il-18 humaine combinee a un anticorps anti-cd20
MA32234A MA31264B1 (fr) 2007-03-23 2009-09-24 Methodes de traitement du cancer comprenant l'administration de l'il-18 humaine en combinaison

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA32234A MA31264B1 (fr) 2007-03-23 2009-09-24 Methodes de traitement du cancer comprenant l'administration de l'il-18 humaine en combinaison

Country Status (21)

Country Link
US (4) US20080274078A1 (fr)
EP (3) EP2136841A4 (fr)
JP (2) JP2010522200A (fr)
KR (2) KR20100015798A (fr)
CN (1) CN101678102A (fr)
AR (2) AR065803A1 (fr)
AU (2) AU2008231114A1 (fr)
BR (2) BRPI0808943A2 (fr)
CA (2) CA2681851A1 (fr)
CL (2) CL2008000818A1 (fr)
CR (2) CR10996A (fr)
DO (2) DOP2009000208A (fr)
EA (2) EA200970884A1 (fr)
IL (2) IL200525A0 (fr)
MA (2) MA31265B1 (fr)
MX (2) MX2009010269A (fr)
NZ (1) NZ579179A (fr)
PE (2) PE20090190A1 (fr)
SG (1) SG171674A1 (fr)
TW (2) TW200906436A (fr)
WO (2) WO2008118733A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399148A1 (fr) * 2000-02-10 2001-08-16 Abbott Laboratories Anticorps de liaison de l'interleukine 18 humaine et procedes de preparation et d'utilisation
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
PE20090190A1 (es) * 2007-03-23 2009-03-22 Smithkline Beecham Corp Combinacion de anticuerpos anti-cd20 y polipeptidos de il-18
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
HUE047952T2 (hu) 2014-04-25 2020-05-28 Pf Medicament Ellenanyag-drog konjugátum és alkalmazása rák kezelésében történõ alkalmazásra
HRP20190888T8 (hr) 2014-04-25 2019-10-04 Pierre Fabre Médicament Konjugat antitijela za igf-1r i lijeka i njegova upotreba u liječenju karcinoma
KR101940430B1 (ko) * 2014-08-07 2019-01-18 가꼬우호우징 효고 이카다이가쿠 Il-18과 분자 표적 항체를 병용하는 암 치료약
WO2016126615A1 (fr) * 2015-02-03 2016-08-11 Armo Biosciences, Inc. Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
WO2022115946A1 (fr) * 2020-12-02 2022-06-09 The Royal Institution For The Advancement Of Learning/Mcgill University Applications thérapeutiques d'antagonistes du récepteur du facteur de croissance de type insuline 1 (igf-1)
WO2025033330A1 (fr) * 2023-08-04 2025-02-13 医療革新国際連携株式会社 Thérapie antitumorale par utilisation combinée d'un inhibiteur de chymase et d'une immunothérapie

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69519454T2 (de) 1994-07-14 2001-05-03 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen
JP4004088B2 (ja) 1995-09-26 2007-11-07 株式会社林原生物化学研究所 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質
TW464656B (en) 1994-11-15 2001-11-21 Hayashibara Biochem Lab Interferon-gamma production inducing polypeptide monoclonal antibody, and agent for interferon-gamma susceptive disease
US7135458B1 (en) * 1995-11-15 2006-11-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use
US5680795A (en) 1995-07-05 1997-10-28 Norco Inc. Mechanical drive assembly incorporating counter-spring biassed radially-adjustable rollers
JP4024366B2 (ja) * 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
US6787132B1 (en) * 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
PL366134A1 (en) * 2000-06-15 2005-01-24 Smithkline Beecham Corporation Method for preparing a physiologically active il-18 polypeptide
US20020094323A1 (en) * 2000-10-12 2002-07-18 Kristoffer Hellstrand Methods and compositions for promoting the maturation of monocytes
WO2003068821A2 (fr) * 2002-02-14 2003-08-21 Immunomedics, Inc. Anticorps anti-cd20 et proteines hybrides desdits anticorps, et methodes d'utilisation
WO2003072736A2 (fr) * 2002-02-21 2003-09-04 Duke University Reactifs et methodes therapeutiques de maladies auto-immunes
EP2298338B1 (fr) * 2002-09-16 2012-08-22 Agennix Incorporated Compositions à base de lactoferrine et méthodes de traitement des plaies cutanées.
KR20050073488A (ko) * 2002-10-08 2005-07-13 이뮤노메딕스, 인코오포레이티드 Ⅲ종 항-ｃｅａ 단클론 항체들 및 치료제들을 이용한 조합치료법
BRPI0315295C1 (pt) * 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
EP2261244A3 (fr) * 2003-04-15 2011-02-23 Glaxosmithkline LLC Mutants par substitution de l'interluekine 18 humaine et ces conjugués
US20050075277A1 (en) * 2003-07-10 2005-04-07 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
CA2534639C (fr) * 2003-07-31 2013-07-30 Immunomedics, Inc. Anticorps anti-cd19
CA2604222A1 (fr) * 2005-04-18 2006-10-26 Novo Nordisk A/S Variantes de l'il-21
WO2007009469A2 (fr) * 2005-07-21 2007-01-25 Genmab A/S Analyses de puissance destinees a la liaison d'une substance medicamenteuse d'anticorps a un recepteur fc
WO2008008981A1 (fr) * 2006-07-13 2008-01-17 Zymogenetics, Inc. Traitement de combinaison d'interleukine 21 et d'inhibiteur de tyrosine kinase
EP2059253A4 (fr) * 2006-09-14 2011-09-14 Univ Pennsylvania Modulation de lymphocytes t régulateurs par l'il-18 humaine
PE20090190A1 (es) * 2007-03-23 2009-03-22 Smithkline Beecham Corp Combinacion de anticuerpos anti-cd20 y polipeptidos de il-18

Also Published As

Publication number Publication date
KR20100014530A (ko) 2010-02-10
EP2136841A4 (fr) 2010-07-07
AU2008231114A1 (en) 2008-10-02
KR20100015798A (ko) 2010-02-12
EA200970884A1 (ru) 2010-04-30
TW200906436A (en) 2009-02-16
CL2008000842A1 (es) 2008-10-17
CR10996A (es) 2009-11-12
MX2009010269A (es) 2009-10-12
IL200525A0 (en) 2010-04-29
AR065803A1 (es) 2009-07-01
WO2008118736A1 (fr) 2008-10-02
AU2008231025A1 (en) 2008-10-02
WO2008118733A2 (fr) 2008-10-02
CA2681827A1 (fr) 2008-10-02
CN101678102A (zh) 2010-03-24
JP2010522200A (ja) 2010-07-01
EP2136841A2 (fr) 2009-12-30
IL200863A0 (en) 2010-05-17
DOP2009000208A (es) 2010-03-31
US20090035258A1 (en) 2009-02-05
EP2129398A4 (fr) 2010-04-21
MA31264B1 (fr) 2010-03-01
EP2338514A1 (fr) 2011-06-29
NZ579179A (en) 2011-12-22
CR11075A (es) 2010-03-22
TW200904469A (en) 2009-02-01
CA2681851A1 (fr) 2008-10-02
MX2009010271A (es) 2009-10-12
SG171674A1 (en) 2011-06-29
AR065818A1 (es) 2009-07-01
PE20090190A1 (es) 2009-03-22
PE20090184A1 (es) 2009-03-22
US20080274078A1 (en) 2008-11-06
US20100111945A1 (en) 2010-05-06
US20100196310A1 (en) 2010-08-05
EP2129398A1 (fr) 2009-12-09
EA200970885A1 (ru) 2010-02-26
CL2008000818A1 (es) 2008-09-26
WO2008118733A3 (fr) 2008-11-27
BRPI0808943A2 (pt) 2014-08-26
BRPI0809079A2 (pt) 2019-03-06
DOP2009000220A (es) 2009-10-31
JP2010522239A (ja) 2010-07-01

Similar Documents

Publication Publication Date Title
MA31265B1 (fr) Traitement du cancer au moyen de l'il-18 humaine combinee a un anticorps anti-cd20
MA33470B1 (fr) Polythérapie à base d'un anticorps afucosylé anti-cd20 et de fludarabine et/ou mitoxantrone
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
MA34059B1 (fr) Thérapie anti-angiogénique pour le traitement du cancer des ovaires
GT200500298A (es) Formulaciones de anticuerpos
MA33276B1 (fr) Anticorps spécifiques à la cadhérine-17
EA200802182A1 (ru) Модифицированные гуманизированные антитела против интерлейкина-18
UA105760C2 (uk) Антитіло проти bst2
MA33757B1 (fr) Protéines de liaison à l'antigène de l'il-23 humaine
UA109633C2 (uk) Антитіло людини проти тканинного фактора
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
AR077724A1 (es) Anticuerpos humanos de alta afinidad contra pcsk9
MA34277B1 (fr) Pyrrolobenzodiazépines et conjugués de celles-ci
GT200900167A (es) Anticuerpos humanos contra el ligando 4 de tipo delta humano.
MX2018011832A (es) Metodos y composiciones para uso en diagnostico de pacientes con cancer.
CY1118549T1 (el) Χρηση anti-vegf αντισωματος σε συνδυασμο με χημειοθεραπεια για τη θεραπευτικη αγωγη του καρκινου του μαστου
MA31984B1 (fr) Formulation d'anticorps
CO6710903A2 (es) Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo
CR10730A (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
MA33323B1 (fr) Thérapie adjuvante de cancer
EP2597464A3 (fr) Profilage métabolomique du cancer de la prostate
MA32899B1 (fr) Combinaisons anticancereuses contenant des anticorps reconnaissant specifiquement cd38 et de la cytarabine
MA53069B1 (fr) Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer
EA201100779A1 (ru) Композиции антител к cxcr1 и способы их применения
MA38273A1 (fr) Thérapie de combinaison avec des anticorps anti-her3